Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size to Grow by USD 6.75 Billion | Market Size, Completive Analysis, Industry Segments, Share and Forecast to 2026

Vendor Landscape

The epidermal growth factor receptor (EGFR) inhibitors market report also offers information on several market vendors, including Amgen Inc., Apollomics Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., and Takeda Pharmaceutical Co. Ltd. among others.

Moreover, the market is fragmented and the vendors are deploying growth strategies such as investment in R and D to compete in the market.

• F. Hoffmann La Roche Ltd.- The company offers epidermal growth factor receptor that provides pharmaceuticals, solutions for diagnosis, personalized healthcare, wellness, and other segments. It is a public company headquartered in Switzerland. It is a global company generating USD 66,254.93 million in revenues and has around 100,000 employees. Its revenue from the global epidermal growth factor receptor (EGFR) inhibitors market contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company.

Download Report to know about the market's vendor landscape highlights with a comprehensive list of vendors and their offerings.

Latest Drivers & Trends of the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

• Market Driver:
• Strong prevalence of major cancer indications:

The US reports the highest number of cancer cases in the world. According to the Union for International Cancer Control (UICC), there were 19.1 million cancer cases in 2020, which resulted in 10 million deaths globally. In addition, the number of breast cancer cases increased by 24% in 2020 when compared with 2019. Moreover, the International Agency for Research on Cancer (IARC) has estimated that there will be around 29.4 million cancer cases by 2040, which will result in the death of 16.4 million people due to cancer. Despite the increasing prevalence of cancer, the market still witnesses a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as EGFR inhibitors for the treatment of cancer indications. Such factors are expected to support the market growth during the forecast period.

• Market Trend:
• New research areas:

The high efficacy of EGFR inhibitors toward the treatment of various types of cancer has resulted in the recent approvals of various novel EGFR inhibitors such as IRESSA, TAGRISSO, ERBITUX, TARCEVA, and TYKERB. Various research institutes and pharmaceutical vendors in the market are conducting research on identifying the efficacy of EGFR inhibitors toward the treatment of various indications other than cancer. For instance, the studies in the early stages of clinical trials are helping in the identification of the use of EGFR inhibitors for the treatment of inflammatory diseases and monogenic diseases. New in-vitro research studies have shown that EGFR mutations are responsible for causing indications such as psoriasis, eczema, and atherosclerosis. Such factors are expected to positively impact the market growth in the forecast period.

Find additional information about various other market drivers & trends mentioned in our FREE sample report.

Key Market Segmentation

• Segmentation by Indication:
• Lung Cancer:

The epidermal growth factor receptor (EGFR) inhibitors market share growth by the lung cancer segment will be significant during the forecast period. The strong prevalence of the disease globally will result in an unmet need for therapeutics in the market, which will increase the demand for therapeutic options. This will result in the launch of novel drugs such as EGFR inhibitors for the treatment, thereby supporting the market growth in the coming years.

• Colorectal cancer
• Breast cancer
• Others

Request a FREE Sample of this report for more highlights into the market segments.

Our Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report Covers the Following Areas:

• Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size
• Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Trends 
• Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis

Regional Market Outlook

The market is segmented by Geography (North America, Europe, Asia, and ROW). 43% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for epidermal growth factor receptor (EGFR) inhibitors in North America. Market growth in this region will be faster than the growth of the market in Europe and Rest of World (ROW).

The increasing prevalence of various types of major cancer indications and heavy sales of approved therapeutics will facilitate the epidermal growth factor receptor (EGFR) inhibitors market growth in North America over the forecast period.

Download our FREE sample report for more key highlights on the regional market share of most of the above-mentioned countries.

Need More? Are You Looking for Information Not Covered in This Report?

• Want to understand more about the various research methodology?
• Evaluate a specific segment or region in detail
• Identify key suppliers, customers, or other market players
• Analyze market regulations

Tailor this report according to your needs. Get it done with our $1000 worth of free customization. Speak to Our Analyst Now!

Related Reports:

Global Urinary Drainage Bags Market: The global urinary drainage bags market size will grow by USD 141.88 million. This market report provides a detailed analysis of the market by type, usage, and geography. To get more exclusive research insights: Download Our FREE Sample Report

3D Cardiac Mapping Systems Market by Product and Geography - Forecast and Analysis 2022-2026: The 3D cardiac mapping systems market share is expected to increase by USD 444.5 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.36%. To get more exclusive research insights: Download Our FREE Sample Report

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Indication

• 5.1 Market segments
• Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)

• 5.2 Comparison by Indication
• Exhibit 26: Chart on Comparison by Indication
• Exhibit 27: Data Table on Comparison by Indication

• 5.3 Lung cancer - Market size and forecast 2021-2026
• Exhibit 28: Chart on Lung cancer - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Lung cancer - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Lung cancer - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Lung cancer - Year-over-year growth 2021-2026 (%)

• 5.4 Colorectal cancer - Market size and forecast 2021-2026
• Exhibit 32: Chart on Colorectal cancer - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Colorectal cancer - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Colorectal cancer - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Colorectal cancer - Year-over-year growth 2021-2026 (%)

• 5.5 Breast cancer - Market size and forecast 2021-2026
• Exhibit 36: Chart on Breast cancer - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Breast cancer - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Breast cancer - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Breast cancer - Year-over-year growth 2021-2026 (%)

• 5.6 Others - Market size and forecast 2021-2026
• Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.7 Market opportunity by Indication
• Exhibit 44: Market opportunity by Indication ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 46: Chart on Market share by geography 2021-2026 (%)
• Exhibit 47: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 48: Chart on Geographic comparison
• Exhibit 49: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 France - Market size and forecast 2021-2026
• Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 92: Matrix on vendor position and classification

• 10.3 Amgen Inc.
• Exhibit 93: Amgen Inc. - Overview
• Exhibit 94: Amgen Inc. - Product / Service
• Exhibit 95: Amgen Inc. - Key offerings

• 10.4 Apollomics Inc.
• Exhibit 96: Apollomics Inc. - Overview
• Exhibit 97: Apollomics Inc. - Product / Service
• Exhibit 98: Apollomics Inc. - Key news
• Exhibit 99: Apollomics Inc. - Key offerings

• 10.5 AstraZeneca Plc
• Exhibit 100: AstraZeneca Plc - Overview
• Exhibit 101: AstraZeneca Plc - Product / Service
• Exhibit 102: AstraZeneca Plc - Key news
• Exhibit 103: AstraZeneca Plc - Key offerings

• 10.6 Boehringer Ingelheim International GmbH
• Exhibit 104: Boehringer Ingelheim International GmbH - Overview
• Exhibit 105: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 106: Boehringer Ingelheim International GmbH - Key news
• Exhibit 107: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 108: Boehringer Ingelheim International GmbH - Segment focus

• 10.7 Checkpoint Therapeutics Inc.
• Exhibit 109: Checkpoint Therapeutics Inc. - Overview
• Exhibit 110: Checkpoint Therapeutics Inc. - Business segments
• Exhibit 111: Checkpoint Therapeutics Inc. - Key offerings
• Exhibit 112: Checkpoint Therapeutics Inc. - Segment focus

• 10.8 Eli Lilly and Co.
• Exhibit 113: Eli Lilly and Co. - Overview
• Exhibit 114: Eli Lilly and Co. - Business segments
• Exhibit 115: Eli Lilly and Co. - Key offerings
• Exhibit 116: Eli Lilly and Co. - Segment focus

• 10.9 F. Hoffmann La Roche Ltd.
• Exhibit 117: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 118: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 119: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 120: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 121: F. Hoffmann La Roche Ltd. - Segment focus

• 10.10 Novartis AG
• Exhibit 122: Novartis AG - Overview
• Exhibit 123: Novartis AG - Business segments
• Exhibit 124: Novartis AG - Key offerings
• Exhibit 125: Novartis AG - Segment focus

• 10.11 Pfizer Inc.
• Exhibit 126: Pfizer Inc. - Overview
• Exhibit 127: Pfizer Inc. - Product / Service
• Exhibit 128: Pfizer Inc. - Key news
• Exhibit 129: Pfizer Inc. - Key offerings

• 10.12 Puma Biotechnology Inc.
• Exhibit 130: Puma Biotechnology Inc. - Overview
• Exhibit 131: Puma Biotechnology Inc. - Business segments
• Exhibit 132: Puma Biotechnology Inc. - Key news
• Exhibit 133: Puma Biotechnology Inc. - Key offerings
• Exhibit 134: Puma Biotechnology Inc. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 135: Inclusions checklist
• Exhibit 136: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 137: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 138: Research methodology
• Exhibit 139: Validation techniques employed for market sizing
• Exhibit 140: Information sources

• 11.5 List of abbreviations
• Exhibit 141: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio